Innovating to Meet Unmet Needs

At Mylan, we have a long tradition of innovation.

In fact, we’ve invested more than $3 billion in R&D globally over the last five years. And whether we’re developing more affordable versions of insulins, biologics or respiratory therapies, better health for a better world is our goal.

Scroll

Investing for Now and the Future

Innovation occurs around the clock in multiple R&D sites worldwide. Mylan has:

2 Global R&D Centers
including one in West Virginia
10 Tech-Focused R&D sites

including one in Texas and one in Vermont

>3,000

R&D, Clinical, Medical and Regulatory professionals worldwide

>4,000
patents filed globally
~1,800
more product submissions pending approval worldwide
Mylan beaker
Scroll

Challenging the Status Quo

Mylan africa children

Mylan takes on challenges no one else will, developing innovative, cost-effective and patient-friendly treatments for diseases like cancer, diabetes, HIV/AIDS and more.

For example, lack of refrigeration once meant lack of access to certain antiretroviral (ARV) medicines for millions of HIV/AIDS patients in developing countries. Our scientists responded by making heat-stable formulations.

And Mylan's innovations go way beyond medicines. Our services and patient-support programs address a wide range of health issues.

Scroll

Delivering Medicine the Way Patients Need It

Mylan products
Mylan has the capacity to produce:
>75B

oral solid doses, such as tablets and capsules

>500M

units of injectables

1.3B

units of complex products, such as transdermal patches, topical products and respiratory therapies

From tablets and capsules, injectables and ointments to inhalers and transdermals – Mylan provides patients the medicine they need, the way they need it.

Data as of Q2 2018
Scroll

Driving Access to Advanced Treatments

Mylan is known for producing "difficult-to-develop" medicines. Many are used to treat diseases like cancer, autoimmune disorders, chronic obstructive pulmonary disease (COPD) and diabetes.

Mylan has ~20 biosimilar and insulin analog products on the market or in development worldwide.

Mylan BiosimilarImage

Read more about: